• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Gelatin, Soft Capsule Gelatin, Hard Capsule Gelatin, Pharmaceutical Gelatin-Foodmate
Neohesperidin
Advantame
Cleanroom Bench Horizontal Laminar Flow Hood Airflow Clean Bench
Pharma and Food Grade, USP/FCC Neotame Sweetener E961
Trilobatin

Vaccine biotech Icosavax sets terms for $150 million IPO

firstwordpharmaJuly 23, 2021

Tag: Icosavax , Vaccine , IPO

Icosavax plans to raise $150 million in its initial public offering by offering 10 million shares at a price range of $14 to $16, as reported by NASDAQ.

The company is developing its virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life threatening respiratory diseases. 

Icosavax’s lead program is IVX-A12, a bivalent candidate targeting both respiratory syncytial virus and human metapneumovirus.


Previous:AzurRx BioPharma Announces $3.0 Million Bought Deal Offering of Common Stock

Next:Guidelines Updated for Treatment of Sexually Transmitted Infections

Related News

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Everest Medicines LimitedDecember 20, 2024

Everest Medicines announced NMPA acceptance of NDA for VELSIPITY(R) (etrasimod) to treat moderately to severely active UC.

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

PRNewswireDecember 12, 2024

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

PRNewswireDecember 12, 2024

Vaccine biotech Icosavax sets terms for $150 million IPO | Pharmasources.com

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

PRNewswireDecember 12, 2024

Core8 Group, an Australian leader in high-tech and biotech innovation, has unveiled plans to develop Vietnam's first AI x ESG Hospital, marking a significant milestone in healthcare transformation.

You may like
More>>

Lipoic acid

Lipoic acid
R-alpha-Lipoic Acid

R-alpha-Lipoic Acid
24-carbonyl-1,3-bi-TBS-trans- Calcipotriol

24-carbonyl-1,3-bi-TBS-trans- Calcipotriol
high quality dipotassium glycyrrhizinate from GMP factory in China

high quality dipotassium glycyrrhizinate from GMP factory in China
500ml pp vaccine bottle manufacturer

500ml pp vaccine bottle manufacturer
Tripotassium phosphate(TKP)

Tripotassium phosphate(TKP)
Gardenia Extracts --Geniposide

Gardenia Extracts --Geniposide
Poliomyelitis Vaccine (Vero Cell), Inactivated, Sabin Strains

Poliomyelitis Vaccine (Vero Cell), Inactivated, Sabin Strains
Lipopeptide

Lipopeptide

high quality Glycyrrhizin Dipotassium Salt from GMP factory in China

high quality Glycyrrhizin Dipotassium Salt from GMP factory in China

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service